Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Short Interest Down 5.0% in June

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 3,742,900 shares, a decline of 5.0% from the May 15th total of 3,940,300 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 312,200 shares, the days-to-cover ratio is currently 12.0 days.

Adaptimmune Therapeutics stock traded down $0.17 during trading hours on Friday, reaching $3.27. 183,338 shares of the company’s stock traded hands, compared to its average volume of 160,488. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. Adaptimmune Therapeutics has a fifty-two week low of $3.20 and a fifty-two week high of $14.54. The company has a market cap of $342.34 million, a price-to-earnings ratio of -3.41 and a beta of 1.63. The business’s 50 day moving average price is $3.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. On average, analysts forecast that Adaptimmune Therapeutics will post -1.17 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its position in shares of Adaptimmune Therapeutics by 157.3% in the 4th quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 12,229 shares during the period. Raymond James & Associates raised its holdings in Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock worth $132,000 after buying an additional 8,498 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Adaptimmune Therapeutics by 139.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,341 shares of the biotechnology company’s stock worth $141,000 after buying an additional 15,361 shares during the period. Acadian Asset Management LLC acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth approximately $219,000. Finally, Squarepoint Ops LLC acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth approximately $622,000. Institutional investors and hedge funds own 66.30% of the company’s stock.

Several equities research analysts have recently weighed in on ADAP shares. Leerink Swann lowered shares of Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 target price on the stock. in a report on Tuesday, May 7th. ValuEngine lowered shares of Yext from a “strong-buy” rating to a “buy” rating in a report on Friday, May 10th. BidaskClub lowered shares of Xencor from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 11th. Raymond James decreased their price objective on shares of Adaptimmune Therapeutics from $16.00 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. Finally, Citigroup set a $14.00 price objective on shares of Coty and gave the stock a “hold” rating in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $6.59.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

See Also: What is dollar cost averaging (DCA)?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.